Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AURORA: Pembrolizumab in HCC
NCT03337841Phase 2Unknown
- Sponsor
- Kindai University
- Start
- Nov 2017
- Primary completion
- Oct 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pembrolizumab in hepatocellular carcinoma (HCC), sponsored by Kindai University. Status: unknown.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03337841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03337841.